Enveric signs non-binding term sheets for out-licensing joint disease compounds; up to $82M in milestones

Enveric Biosciences, Inc.

Two non-binding term sheets with undisclosed biotech to out-license cannabinoid-COX-2 conjugates for joint disease (osteoarthritis, rheumatoid arthritis).
Pharma license potential milestones up to ~$61M; non-pharma up to ~$21M; combined up to ~$82M.
Royalty rates: pharma 2.5%-10%, non-pharma 0.25%-7% on future sales; licensee funds all development.
CEO Joseph Tucker highlights second company to license Enveric assets; definitive agreements remain to be negotiated.
Enveric focuses on neuroplastogenic therapeutics; out-licensing diversifies revenue from its asset portfolio.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.